Design, Synthesis, QSAR Studies of some DPP-IV Inhibitors

Diabetes mellitus (DM) is one of the most common chronic disorder with increasing prevalence worldwide. Different classes of oral anti-hyperglycemic agents with nearly equipotent efficacy are now available; however, almost all of them are associated with one or more adverse effects. The new approaches in management of type 2 DM (T2DM) are based upon the effects of incretin hormones; Glucagon-Like Peptide-1 (GLP-1), Glucose-dependent insulinotropic peptide (GIP) and dipeptidyl peptidase (DPP-IV) inhibitors, which act via enhancing the incretin secretion. QSAR is the computer-based mathematical model which establishes a correlation between structure and its biological activity. In present studies, QSAR of one of the reported triazolopiperazine based beta-aminoamides have been studied. In present studies, an attempt was made to synthesize the novel and selective 3-amino-1-(8- (cyclopropyl(3-mercapto-4H-1,2,4-triazol-4-ylamino)methyl)-2-(trifluoromtrifluromethyl)-5,6,7,8-tetrahydro-imidazolo(4,5a)-piperidine.The details of the regressional analysis, QSAR, rationale behind design, synthesis, structural characterisation and DPP- IV enzyme inhibitory activity are presented.

Autorentext

Mrs. Ketaki S. Dhane Asst. Prof in Department of Pharmaceutical Chemistry at Indira Institute of pharmacy Sadavali affiliated to Mumbai University, Done B. Pharm from Shivaji University and M. Pharm from Savitribai Phule Pune University and pursuing Ph.D. from Jaipur National University, Rajasthan, having a total of 9 years of teaching experience.